Company: GHRS
Filing Date: 2025-02-05
Form Type: 424B5
Source: 0001140361-25-003183
Chunk: 6

Company: GH Research PLC
Filing Date: 2025-02-05
Form: 424B5
Chunk 6
---
 D02 RY95, Ireland, and our telephone number is + 353 1 437 8334. Our website address is www.ghres.com. We do not incorporate the information on or accessible through our website into this prospectus supplement, and you should not consider any information on, or that can be accessed through, our website as part of this prospectus supplement. We are required to file reports and other information with the SEC, including annual reports on Form 20-F and reports on Form 6-K. The SEC maintains an Internet site at www.sec.gov that contains reports, proxy and information statements and other information we have filed electronically with the SEC.

S-6

TABLE OF CONTENTS

THE OFFERING Ordinary shares offered by us 10,000,000 ordinary shares. Option to purchase additional shares We have granted the underwriters a 30-day option to purchase up to 1,500,000 additional ordinary shares from us at the public offering price, less underwriting discounts and commissions. Ordinary shares to be issued and outstanding immediately after this offering 62,028,145 ordinary shares (or 63,528,145 ordinary shares if the underwriters’ option to purchase additional shares is exercised in full). Use of proceeds We estimate that our net proceeds from this offering will be approximately $139.8 million (or $160.8 million if the underwriters’ option to purchase additional shares is exercised in full), after deducting underwriting discounts and commissions and estimated offering expenses payable by us. We intend to use the net proceeds from this offering to strategically invest in research, clinical and technical development of current and/or additional product candidates, working capital, capital expenditures and general corporate purposes. See “Use of Proceeds.” Risk factors Investing in our ordinary shares involves a high degree of risk. See the “Risk Factors” section in this prospectus supplement and in the documents incorporated by reference in this prospectus supplement and the accompanying prospectus for a discussion of factors you should consider before deciding to invest in our ordinary shares. Nasdaq symbol “GHRS” In this prospectus supplement, unless otherwise indicated, the number of ordinary shares outstanding after this offering is based on 52,028,145 ordinary shares issued and outstanding as of September 30, 2024, and excludes:

| • | 768,182 ordinary shares issuable upon exercise of options outstanding under our equity incentive plan, or our Share Option Plan, as of September 30, 2024, at a weighted average exercise price of approximately